Food allergy biotech DBV is running out of cash, with phase 3 trials underway

DBV Technologies, a French biotech working on a treatment for food allergies, says it's running out of cash.

The disclosure came via a going concern note in the company’s fourth-quarter and full-year 2023 earnings report on Friday, with DBV saying it doesn’t have enough money to keep the lights on for a full 12 months.